Onodrim Industries, SRTD Biotech, T-Therapeutics — $300M for defence, €31.5M for RNA and $133M for bispecifics — Daily News November 9, 2026
About this episode
Three European rounds fund different ways of building capacity: consolidating the defence industrial base, making RNA therapies selective and advancing bispecific drugs towards the clinic. Capital speeds up execution, but integrated acquisitions, preclinical evidence and clinical results remain the decisive tests.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Main news
Startups mentioned
Onodrim Industries
Amsterdam company founded by Palantir alumni that buys controlling stakes in European industrial firms to expand their capacity and growth.
SRTD Biotech
German biotech developing selectively expressed RNA for oncology, autoimmune disease and fibrosis.
T-Therapeutics
University of Cambridge spinout using its OpTiMus platform to generate fully human T-cell receptors and turn them into drugs.